EPHB4 and neoplasm: Additionally, the development of EphB4 inhibitors for clinical use faces several challenges, such as the difficulty in detecting and inhibiting the protein–protein interactions on the surface of the EphB4-ephinB2 complex with small molecules, the low selectivity of small molecular compounds targeting ATP binding sites, and the potential to block the tumor suppressor activity of EphB4 [83].